Literature DB >> 19106532

[Management of pulmonary recurrence of hepatocellular carcinoma after receiving a living-donor liver transplantation--a case report].

Tadafumi Asaoka1, Shigeru Marubashi, Keizo Dono, Naoki Hama, Chiwan Kim, Shogo Kobayashi, Yutaka Takeda, Hiroaki Nagano, Koji Umeshita, Morito Monden, Yuichiro Doki, Masaki Mori.   

Abstract

We report on the treatment experience of five living-donor liver transplantation (LDLT) recipients for hepatocellular carcinoma (HCC) with pulmonary metastases. Between March 1998 and December 2007, five patients who underwent LDLT for HCC were identified with a routine follow-up of pulmonary metastases: Two patients underwent a radical resection for pulmonary recurrence of HCC, Two patients were only observed by palliative treatment, and one patient had chemotherapy using S-1/IFN. The survival range from pulmonary recurrence of HCC was 7.5 to 43.0 months and the median survival time was 18.9 months. Only one of the 5 patients who underwent a surgical resection of pulmonary recurrence is still alive without a new recurrence for a long period of time.

Entities:  

Mesh:

Year:  2008        PMID: 19106532

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Resection of lung metastases from hepatocellular carcinoma after living donor liver transplantation: report of two cases.

Authors:  Junichi Togashi; Yasuhiko Sugawara; Taku Aoki; Sumihito Tamura; Junichi Kaneko; Jun Nakajima; Atsushi Sano; Norihiro Kokudo
Journal:  Surg Today       Date:  2011-08-26       Impact factor: 2.549

2.  Pulmonary Resection for Metastasis of Hepatocellular Carcinoma Recurring After Liver Transplant: An Italian Multicenter Experience.

Authors:  Federica Invenizzi; Massimo Iavarone; Maria Francesca Donato; Alessandra Mazzucco; Massimo Torre; Serena Conforti; Arianna Rimessi; Claudio Zavaglia; Marco Schiavon; Giovanni Comacchio; Federico Rea; Riccardo Boetto; Umberto Cillo; Daniele Dondossola; Luciano De Carlis; Pietro Lampertico; Mario Nosotti; Paolo Mendogni
Journal:  Front Oncol       Date:  2020-04-15       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.